このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Sarepta Therapeutics マネジメント
マネジメント 基準チェック /44
現在、CEO に関する十分な情報がありません。
主要情報
Doug Ingram
最高経営責任者
US$1.7m
報酬総額
| CEO給与比率 | 48.1% |
| CEO在任期間 | 7yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 3.5yrs |
| 取締役会の平均在任期間 | 8yrs |
経営陣の近況
Recent updates
Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08
Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
報酬と市場: Dougの 総報酬 ($USD 1.66M ) は、 US市場 ($USD 13.52M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Dougの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Doug Ingram (61 yo)
7yrs
在職期間
US$1,661,338
報酬
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7yrs | US$1.66m | 0.41% $ 61.7m | |
| Executive VP & CFO | 3.5yrs | US$3.71m | 0.042% $ 6.3m | |
| Executive VP & Chief Technical Operations Officer | 1.5yrs | US$3.52m | 0.018% $ 2.7m | |
| Executive VP | 3.5yrs | US$3.72m | 0.076% $ 11.4m | |
| Executive VP | 3.5yrs | US$3.58m | 0.018% $ 2.7m | |
| Executive Director of Investor Relations and Corporate Communications | no data | データなし | データなし | |
| Executive VP & Chief People Officer | 2.7yrs | データなし | データなし | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 4.8yrs | データなし | データなし | |
| Executive VP & Chief Customer Officer | 3.5yrs | データなし | 0.023% $ 3.5m | |
| Senior VP | 1.4yrs | データなし | データなし | |
| Controller & VP | 7.3yrs | US$911.89k | データなし | |
| Senior Manager of Investor Relations | no data | データなし | データなし |
3.5yrs
平均在職期間
50yo
平均年齢
経験豊富な経営陣: SRPTの経営陣は 経験豊富 であると考えられます ( 3.5年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7yrs | US$1.66m | 0.41% $ 61.7m | |
| Independent Chairwoman | 15.3yrs | US$594.99k | 0.20% $ 29.2m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14yrs | US$546.99k | 0.022% $ 3.3m | |
| Independent Director | 9yrs | US$563.65k | 3.36% $ 502.4m | |
| Member of Strategic & Scientific Advisory Board | 8.8yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし | |
| Member of Strategic & Scientific Advisory Board | 8.8yrs | データなし | データなし | |
| Independent Non-Employee Director | 9yrs | US$553.34k | 0.017% $ 2.6m | |
| Member of Strategic & Scientific Advisory Board | 7.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.5yrs | データなし | データなし | |
| Member of Strategic & Scientific Advisory Board | 7.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 4.6yrs | データなし | データなし |
8.0yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: SRPTの 取締役会 は 経験豊富 であると考えられます ( 8年の平均在任期間)。